Statistics from Altmetric.com
Are corticosteroids or monoclonal antibodies better to prevent relapse in NMO spectrum disorders?
Evidence for the treatment of neuromyelitis optica (NMO) spectrum disorder (NMOSD) has accumulated in the past decades. Case series and open-label studies suggest the efficacy of various immunosuppressive agents and more recently, monoclonal antibodies for attack prevention. Oral corticosteroids combined with azathioprine, mycophenolate mofetil or rituximab are an efficient widely used treatment.1 However, because of the lack of randomised controlled trials (RCT) to evaluate the efficacy and safety of any drugs described above, there is no established therapy.
In their JNNP paper, Stellmann et al 2 (German NEMOS (Neuromyelitis Optica Study) Group) reported a retrospective cohort study, including 150 patients with NMOSD (87% aquaporin-4 antibody positive), for attack prevention …
Contributors MM has made a draft of the manuscript and AU and SK have supervised it.
Funding This work was supported in part by the Health and Labour Sciences Research Grant on Intractable Diseases (Neurodegenerative Diseases) from the Ministry of Health, Labour and Welfare of Japan.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.